title: [The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention].
abstract: OBJECTIVE
  The purpose of the study is to prospectively investigate the safety and efficacy of anticoagulation with enoxaparin (Clexane) in UA/NQMI patients undergoing PCI procedures.
  
  
  METHODS
  UA/NQMI patients received Clexane 1 mg/kg, subcutaneously, q12h for at least 48 hours, the coronary angiography was immediately followed by PCI when indicated and is performed within 8 h after the morning injection. No additional UFH or LMWH was used during or after PCI. Blood samples were taken for further measurement of the anti-Xa activity in 176 patients.
  
  
  RESULTS
  507 UA/NQMI patients were included in the study. 176 patients (93.2%) of the average anti-Xa activity value was > 0.5 IU/ml. During follow-up within 30 days, 3.2% of the patients experienced AMI and 6.7% of the patients recurrent UAP. One patient (0.2%) received revascularization and another died of duodenum perforation. The rate of minor hemorrhage was 4.7% (24 patients). In 30-days follow up, one experienced NQMI and 1 recurrent UA among angiography patients.
  
  
  CONCLUSIONS
  Subcutaneous Enoxaparin given at least for 48 hours before PCI with out additional UFH or LMWH during or after PCI was both safe and effective in high risk UA/NQMI patients.
authors.affiliation: The People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Da-yi
authors.initials: DY
authors.lastname: Hu
authors.forename: Xiu-li
authors.initials: XL
authors.lastname: Zhao
authors.forename: San-qing
authors.initials: SQ
authors.lastname: Jia
authors.forename: Tian-chang
authors.initials: TC
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Fan-Long
authors.initials: FL
authors.lastname: Kong
authors.forename: Bu-xing
authors.initials: BX
authors.lastname: Chen
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin